GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Cost of Goods Sold

Mayne Pharma Group (ASX:MYX) Cost of Goods Sold : A$169.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group Cost of Goods Sold?

Mayne Pharma Group's cost of goods sold for the six months ended in Jun. 2024 was A$87.5 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Jun. 2024 was A$169.6 Mil.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mayne Pharma Group's Gross Margin % for the six months ended in Jun. 2024 was 56.41%.

Cost of Goods Sold is also directly linked to Inventory Turnover. Mayne Pharma Group's Inventory Turnover for the six months ended in Jun. 2024 was 1.05.


Mayne Pharma Group Cost of Goods Sold Historical Data

The historical data trend for Mayne Pharma Group's Cost of Goods Sold can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Cost of Goods Sold Chart

Mayne Pharma Group Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cost of Goods Sold
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.49 205.58 253.77 100.10 169.62

Mayne Pharma Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cost of Goods Sold Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 146.64 93.27 6.83 82.14 87.48

Mayne Pharma Group Cost of Goods Sold Calculation

Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.

Cost of Goods Sold for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$169.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mayne Pharma Group  (ASX:MYX) Cost of Goods Sold Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mayne Pharma Group's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=(Revenue - Cost of Goods Sold) / Revenue
=(200.711 - 87.481) / 200.711
=56.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:

Mayne Pharma Group's Inventory Turnover for the six months ended in Jun. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.


Mayne Pharma Group Cost of Goods Sold Related Terms

Thank you for viewing the detailed overview of Mayne Pharma Group's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.


Mayne Pharma Group Business Description

Traded in Other Exchanges
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.